Association of Alzheimer's Disease and Insulin Resistance in King Abdulaziz Medical City, Jeddah
- PMID: 34956794
- PMCID: PMC8693831
- DOI: 10.7759/cureus.19811
Association of Alzheimer's Disease and Insulin Resistance in King Abdulaziz Medical City, Jeddah
Abstract
Background Alzheimer's disease (AD) and insulin resistance (IR) are common in the elderly. IR reduces the ability of insulin to work effectively on target tissues. This results in hyperglycemia, increased triglyceride levels, decreased high-density lipoprotein (HDL) levels, elevated blood pressure, and central obesity, a condition known as metabolic syndrome (MetS). MetS eventually affects cognition, but its relationship with AD is unclear. Therefore, we studied the association between AD and IR and the relation between AD and diabetic patients treated with insulin. Methods This was a record-based retrospective cohort study using data from King Abdulaziz Medical City, Jeddah, Ministry of National Guards-Health Affairs. for all patients with dementia and AD, from 2009 to 2018. We examined 354 patient files. The triglyceride-glucose (TyG) index was used for the assessment of IR. Results There was no significant association between patients' demographic data, glycated hemoglobin, and co-morbidities and developing AD. Statistical models showed that, after adjustment for age, patients with IR had a significantly higher likelihood of AD (adjusted OR = 1.4; 95% CI: 1.01-2.33). After multivariate adjustment, patients with IR still had a 20% higher probability of developing AD than others (adjusted OR = 1.2; 95% CI: 1.0-3.1). Conclusion These results suggest that AD is associated with IR. Moreover, the association may be confounded by many patient-related factors.
Keywords: alzheimer’s disease; dementia; insulin resistance; metabolic syndrome; tyg index.
Copyright © 2021, Faqih et al.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures
References
-
- Alzheimer's disease: a review from the pathophysiology to diagnosis, new perspectives for pharmacological treatment. Dos Santos Picanco LC, Ozela PF, de Fatima de Brito Brito M, et al. Curr Med Chem. 2018;25:3141–3159. - PubMed
-
- 2021 Alzheimer's disease facts and figures. Alzheimer's Association. Alzheimers Dement. 2021;17:327–406. - PubMed
-
- Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J. New York, United States: McGraw Hill Medical; 2021. Harrison’s Principles of Internal Medicine, 20e.
-
- Metabolic syndrome and its effect on the brain: possible mechanism. Arshad N', Lin TS, Yahaya MF. CNS Neurol Disord Drug Targets. 2018;17:595–603. - PubMed
LinkOut - more resources
Full Text Sources